osteosarcoma

Denosumab Shows Insufficient Activity in Recurrent Osteosarcoma: Results from a Children’s Oncology Group Phase 2 Trial

A Phase 2 trial by the Children’s Oncology Group found that denosumab, despite its success in other bone-related conditions, failed to meet efficacy benchmarks for recurrent or refractory osteosarcoma, showing no objective responses i

SMARCAL1 Emerges as a Novel Osteosarcoma Predisposition Gene: Large Study Validates DNA Repair Variation in Pediatric Cancer Risk